Real-world evidence demonstrates that 21 cases of IBD emerged in patients undergoing IL-17 therapy with secukinumab and ixekizumab for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis (64). This evidence concerns the gene IL17A and psoriasis.